Sökning: onr:"swepub:oai:gup.ub.gu.se/77923" > Aspirin and extende...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 08195naa a2201093 4500 | |
001 | oai:gup.ub.gu.se/77923 | |
003 | SwePub | |
008 | 240528s2008 | |||||||||||000 ||eng| | |
009 | oai:DiVA.org:oru-81162 | |
009 | oai:prod.swepub.kib.ki.se:117567180 | |
024 | 7 | a https://gup.ub.gu.se/publication/779232 URI |
024 | 7 | a https://doi.org/10.1056/NEJMoa08050022 DOI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-811622 URI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1175671802 URI |
040 | a (SwePub)gud (SwePub)orud (SwePub)ki | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Sacco, R. L.u Miller School of Medicine, University of Miami, Miami, United States; Miller School of Medicine, University of Miami, Miami, United States,McMaster University, Hamilton, ON, Canada4 aut |
245 | 1 0 | a Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke |
264 | 1 | a Boston :b Massachusetts medical society,c 2008 |
520 | a BACKGROUND: Recurrent stroke is a frequent, disabling event after ischemic stroke. This study compared the efficacy and safety of two antiplatelet regimens--aspirin plus extended-release dipyridamole (ASA-ERDP) versus clopidogrel. METHODS: In this double-blind, 2-by-2 factorial trial, we randomly assigned patients to receive 25 mg of aspirin plus 200 mg of extended-release dipyridamole twice daily or to receive 75 mg of clopidogrel daily. The primary outcome was first recurrence of stroke. The secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes. Sequential statistical testing of noninferiority (margin of 1.075), followed by superiority testing, was planned. RESULTS: A total of 20,332 patients were followed for a mean of 2.5 years. Recurrent stroke occurred in 916 patients (9.0%) receiving ASA-ERDP and in 898 patients (8.8%) receiving clopidogrel (hazard ratio, 1.01; 95% confidence interval [CI], 0.92 to 1.11). The secondary outcome occurred in 1333 patients (13.1%) in each group (hazard ratio for ASA-ERDP, 0.99; 95% CI, 0.92 to 1.07). There were more major hemorrhagic events among ASA-ERDP recipients (419 [4.1%]) than among clopidogrel recipients (365 [3.6%]) (hazard ratio, 1.15; 95% CI, 1.00 to 1.32), including intracranial hemorrhage (hazard ratio, 1.42; 95% CI, 1.11 to 1.83). The net risk of recurrent stroke or major hemorrhagic event was similar in the two groups (1194 ASA-ERDP recipients [11.7%], vs. 1156 clopidogrel recipients [11.4%]; hazard ratio, 1.03; 95% CI, 0.95 to 1.11). CONCLUSIONS: The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel. There is no evidence that either of the two treatments was superior to the other in the prevention of recurrent stroke. (ClinicalTrials.gov number, NCT00153062.) | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Allmänmedicin0 (SwePub)302242 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex General Practice0 (SwePub)302242 hsv//eng |
653 | a Aged | |
653 | a Angiotensin-Converting Enzyme Inhibitors/therapeutic use | |
653 | a Aspirin/*administration & dosage/adverse effects | |
653 | a Benzimidazoles/therapeutic use | |
653 | a Benzoates/therapeutic use | |
653 | a Brain Ischemia/epidemiology/prevention & control | |
653 | a Delayed-Action Preparations | |
653 | a Dipyridamole/adverse effects/*therapeutic use | |
653 | a Double-Blind Method | |
653 | a Drug Therapy | |
653 | a Combination | |
653 | a Factor Analysis | |
653 | a Statistical | |
653 | a Female | |
653 | a Hemorrhage/chemically induced | |
653 | a Humans | |
653 | a Kaplan-Meiers Estimate | |
653 | a Male | |
653 | a Middle Aged | |
653 | a Myocardial Infarction/epidemiology | |
653 | a Platelet Aggregation Inhibitors/administration & dosage/adverse | |
653 | a effects/*therapeutic use | |
653 | a Proportional Hazards Models | |
653 | a Recurrence/prevention & control | |
653 | a Risk | |
653 | a Stroke/*drug therapy/epidemiology/prevention & control | |
653 | a Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use | |
653 | a Vascular Diseases/mortality | |
700 | 1 | a Diener, H. C.u University of Duisberg-Essen, Essen, Germany4 aut |
700 | 1 | a Yusuf, S.u McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada4 aut |
700 | 1 | a Cotton, D.u Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, United States4 aut |
700 | 1 | a Ounpuu, S.u Boehringer Ingelheim, Burlington, ON, Canada4 aut |
700 | 1 | a Lawton, W. A.u Boehringer Ingelheim, Bracknell, United Kingdom4 aut |
700 | 1 | a Palesch, Y.u Medical University of Soudi Carolina, Charleston, United States4 aut |
700 | 1 | a Martin, R. H.u Medical University of Soudi Carolina, Charleston, United States,Boehringer Ingelheim, Stockholm, Sweden4 aut |
700 | 1 | a Albers, G. W.u Stanford University, Medical Center, Palo Alto, CA, United States4 aut |
700 | 1 | a Bath, P.u University of Nottingham, Nottingham, United Kingdom4 aut |
700 | 1 | a Bornstein, N.u Ichilov Medical Center, Tel Aviv, Israel4 aut |
700 | 1 | a Chan, B. P.u National University Hospital, Singapore, Singapore,St. Johns's Medical College, Bangalore, India4 aut |
700 | 1 | a Chen, S. T.u Chang Gung Memorial Hospital, Tapei, Taiwan4 aut |
700 | 1 | a Cunha, L.u Hospitais da Universidade de Coimbra, Coimbra, Portugal4 aut |
700 | 1 | a Dahlöf, Björn,d 1953u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine,Sahlgrenska University Hospital-Östra, Göteborg, Sweden4 aut0 (Swepub:gu)xdahbj |
700 | 1 | a De Keyser, J.u University Medical Center Groningen, Groningen, Netherlands4 aut |
700 | 1 | a Donnan, G. A.u University of Melbourne, Heidelberg West, Australia4 aut |
700 | 1 | a Estol, C.u Neurological Center for Treatment and Research, Buenos Aires, Argentina4 aut |
700 | 1 | a Gorelick, P.u University of Illinois, Chicago, United States4 aut |
700 | 1 | a Gu, V.u Boehringer Ingelheim Shanghai Pharmaceuticals, Shanghai, China4 aut |
700 | 1 | a Hermansson, K.4 aut |
700 | 1 | a Hilbrich, L.u Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, United States4 aut |
700 | 1 | a Kaste, M.u Helsinki University, Central Hospital, Helsinki, Finland4 aut |
700 | 1 | a Lu, C.u Huashan Hospital, Shanghai, China4 aut |
700 | 1 | a Machnig, T.u Boehringer Ingelheim, Ingelheim, Germany4 aut |
700 | 1 | a Pais, P.4 aut |
700 | 1 | a Roberts, R.4 aut |
700 | 1 | a Skvortsova, V.u Russian State Medical University, Moscow, Russian Federation4 aut |
700 | 1 | a Teal, P.u University of British Columbia, Vancouver, Canada4 aut |
700 | 1 | a Toni, D.u University La Sapienza, Rome, Italy4 aut |
700 | 1 | a VanderMaelen, C.u Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, United States4 aut |
700 | 1 | a Voigt, T.u Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, United States4 aut |
700 | 1 | a Weber, M.u SUNY Downstate College of Medicine, New York, United States4 aut |
700 | 1 | a Yoon, B. W.u Seoul National University Hospital, Seoul, South Korea4 aut |
700 | 1 | a von Euler, Mia,d 1967- |
710 | 2 | a Miller School of Medicine, University of Miami, Miami, United States; Miller School of Medicine, University of Miami, Miami, United Statesb McMaster University, Hamilton, ON, Canada4 org |
773 | 0 | t New England Journal of Medicined Boston : Massachusetts medical societyg 359:12, s. 1238-51q 359:12<1238-51x 1533-4406x 0028-4793 |
856 | 4 | u https://doi.org/10.1056/NEJMoa0805002y Fulltext |
856 | 4 8 | u https://gup.ub.gu.se/publication/77923 |
856 | 4 8 | u https://doi.org/10.1056/NEJMoa0805002 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-81162 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:117567180 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.